香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 A 股代码：688235 A 股简称：百济神州 公告编号：2025-028 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 2025年半年度主要财务数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特别提示： 本公告所载的百济神州有限公司（以下简称"百济神州"或"公司"）2025 年半年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司 2025 年半年度报告中披露的数据为准，提请投资者注意投 ...

Investment Rating - The investment rating for the company is "Buy" [6] Core Insights - The company reported a revenue of 27.214 billion yuan for 2024, an increase of 56.19% year-on-year, and a net loss of 4.978 billion yuan, which is a reduction of 1.738 billion yuan compared to the previous year [1] - The growth in product revenue is primarily attributed to the sales of self-developed products Baiyueze® (Zebutinib capsules) and Baizean® (Tislelizumab injection), as well as sales growth from Amgen authorized products [2] - The company is actively expanding in overseas markets, with Baiyueze® having been approved in over 70 markets globally, treating more than 180,000 patients [3] - The company has a robust pipeline with several innovative products, including Sonrotoclax, which is undergoing multiple potential registration trials, and BGB-16673, a BTK degrader that has received FDA fast track designation [4][5] Financial Summary - The company forecasts revenues of 34.938 billion yuan, 42.048 billion yuan, and 48.165 billion yuan for 2025, 2026, and 2027 respectively, representing year-on-year growth rates of 28%, 20%, and 15% [9] - The projected net profit for 2025 is 410 million yuan, with significant growth expected in subsequent years, reaching 3.567 billion yuan in 2026 and 6.291 billion yuan in 2027 [11] - The earnings per share (EPS) are expected to be 0.29 yuan for 2025, 2.55 yuan for 2026, and 4.49 yuan for 2027, indicating a strong recovery and growth trajectory [11] Market Performance - The company's stock closed at 246.91 yuan, with a 52-week high of 258.0 yuan and a low of 111.22 yuan [6] - The total market capitalization is approximately 345.788 billion yuan [6]